The Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance (PrIMAVeRa) project assembles a highly skilled and interdisciplinary consortium with complementary expertise. The consortium consists of a broad range of universities, research organisations, public-health bodies, non-profit organisations, small- and medium-sized enterprises, and three EFPIA industry partners. The project is coordinated by the European Vaccine Initiative (EVI), a non-profit vaccine-development organisation with extensive experience managing large, multi-partner research consortia. All participants have successfully collaborated with industrial partners in multiple contexts. Scientific leadership is provided the University Medical Center Utrecht (UMCU), one of Europe’s leading academic institutions in the field of AMR.

​

PrIMAVeRa includes leading European academic institutions in mathematical modelling of infectious diseases — UMCU, Danmarks Tekniske Universitet (DTU), the UK Health Security Agency (UKHSA), and Institut Pasteur (IP), one of the key modelling partners in the consortium.

It includes institutions with expertise in the clinical and epidemiological aspects of antimicrobial resistance — UMCU, Université de Genève (UNIGE), Università di Verona (UNIVR), Servicio Andaluz de Salud (SAS), Université Grenoble Alpes (UGA), and Kauno Klinikos (KK).

It also brings together organisations with strong expertise in vaccine development — EVI and the University of Oxford (UOXF) — and monoclonal antibodies (mAbs) — Instituto de Salud Carlos III (ISCIII) and UGA.

 

Several partners contribute expertise in public health, surveillance, and AMR strategy — UKHSA, ISCIII, and Kauno Klinikos.  In addition, multiple partners — Eberhard Karls Universität Tübingen (UT), UNIVR, SAS, and Life Science Network (LSN) — provide well-established capabilities in creating and managing sustainable database and bioinformatics platforms. UKHSA and UOXF contribute significant expertise in health economics and cost-effectiveness analysis.  ​The consortium also benefits from the participation of ECRAID, which provides clinical and epidemiological data to support model development and validation. LSN, a non-profit SME, brings a proven track record in delivering bioinformatic solutions.

​

Finally, the consortium includes three EFPIA partners — GSK, Janssen Vaccines & Prevention B.V., and Pfizer — bringing industrial insight in vaccine and mAb development and supporting the translation of scientific results into policy-relevant impact.